18 RESULTS
Go to another page:
COMMENT Readers should see comments made earlier this year on the same topic, i.e., my own comment regarding labs at Johns Hopkins and Massachussetts General Hospital that have not seen Aβ or tau pathology in the retina of AD subjects (see references below). Our ...
COMMENT Multicenter studies with enforced blinding of results assessment will be necessary to resolve the discrepancies in reports from different labs. As mentioned in this paper, a very well respected Johns Hopkins group (Ho et al., 2013) found no evidence for ...
COMMENT The sensitivity and specificity of tau tracers for human tau pathology cannot be known until there have been a substantial number of imaged patients with autopsies and neuropathological diagnoses. Clinical diagnostic accuracy for non-Alzheimer's ...
COMMENT This is an impressive result, agreed. Just would like to point out that the most likely and earliest entry point for an exogenous process would be through the olfactory bulb, not the gut. Our thorough survey of the peripheral nervous system in subjects ...
COMMENT I think the results raise several questions and have some implications for the disease in humans, but I think it is also exciting that some of the implications and hypotheses arising from the finding can be tested in the transgenic mouse model used. For ...
COMMENT I would note that since the overall prevalence of melanoma in Parkinson's disease (PD) is pretty low, it is difficult to see a large role for melanoma-related mechanisms in PD, or vice versa. Also, the extra medical attention that a subject gets ...
COMMENT Interesting paper and nice to see some experimental work being done in this area. I would like to refer readers in this field to our recent papers (below), which confirm earlier work by several investigators that olfactory bulb is universally affected in ...
COMMENT This paper describes a new staging system for all Lewy body disorders and has been badly needed as the two prior major staging systems have failed to classify 40-60 percent of cases. The major differences from prior staging methods are that the rules for ...
COMMENT These new contributions to the history of Alzheimer disease further illuminate the setting in which Alzheimer made his original observations. I look forward to reading the issue coming out of the Tubingen conference. Many thanks to Andre Delacourte for ...
COMMENT This interesting study suggests a molecular mechanism that may explain how CAA contributes to dementia. Clinical studies have indicated that CAA contributes to the dementia in AD, and it has been apparent for decades that CAA eventually results in ...
COMMENT The paper by LaFerla and colleagues adds to considerable evidence suggesting that M1 receptor activation leads to decreased amyloidogenic processing of APP while reduced M1 receptor activation, by means of either pharmacological agents or cholinergic ...
COMMENT The Alzheimer's Disease Cooperative Study Group MCI trial results regarding donepezil are very encouraging and should be used to stimulate a primary prevention trial. The New England Journal report did not offer a molecular mechanism to explain ...
COMMENT This data confirms our work, done in collaboration with Abraham Fisher, showing that AF267B and two other of his M1 agonists (AF102B, AF150S) all lower CSF and cortical Aβ concentrations in normal rabbits [1]. This confirms many years of in vitro work ...
COMMENT The epidemiological evidence should now be regarded as strongly against a protective role for smoking in Alzheimer's disease. Although several early prevalence studies showed that AD was less prevalent in elderly smokers, at least one large incidence ...
COMMENT The NEJM article is good for reminding us that blocking muscarinic receptors may impair cognition and alter perception in anyone, but especially in the elderly. As loss of cortical cholinergic afferents is a normal aging change in humans, the elderly are ...
Go to another page:
